This paper presents a unified, next‑generation therapeutic framework for androgenetic alopecia (AGA), integrating PROTAC‑mediated androgen receptor (AR) degradation with regenerative and micro‑environmental strategies. It provides the first comprehensive analysis of GT20029 as a topical AR‑PROTAC, compares degradation versus antagonism, and evaluates early‑intervention models based on genetic predisposition and pre‑miniaturization biomarkers. The work synthesizes stem‑cell biology, dermal papilla senescence, perifollicular fibrosis, and niche‑engineering approaches into a three‑phase protocol (stabilization, reversal, maintenance). A comparative development timeline (near‑, mid‑, and long‑term therapies) and a set of testable hypotheses are proposed to guide future research, clinical translation, and regenerative integration in AGA.